Yasushi Horimasu

11PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsHumoural immunology and immunochemistryDeep learning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 09, 2026
Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs.

|Jun 04, 2026
Baseline Neutrophil-To-Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non-Small Cell Lung Cancer: A Two-Cohort Study With Retrospective Discovery and Prospective Validation.

|Dec 05, 2025
Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib.

Kei Kagawa, Takeshi Masuda, Kiyofumi Shimoji

|Nov 06, 2025
Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.

Masahiko Sumii, Takeshi Masuda, Kiyofumi Shimoji

|Feb 25, 2023
Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition.

Kentaro Tokumo, Takeshi Masuda, Taku Nakashima

|Nov 29, 2022
Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis.

Hiroki Tanahashi, Kakuhiro Yamaguchi, Koji Kurose

Pageof 2

Frequent Collaborators

8 joint publications

Hiroshi Iwamoto

8 joint publications

Kakuhiro Yamaguchi

7 joint publications

Taku Nakashima

7 joint publications

Takeshi Masuda